Tag: small population trials

Use of Historical Controls in Rare Disease Regulatory Submissions

August 27, 2025

Use of Historical Controls in Rare Disease Regulatory Submissions Leveraging Historical Controls in Orphan Drug Trial Designs Introduction: Why Historical Controls Matter in Rare Disease Trials Rare disease clinical trials frequently face recruitment challenges due to small patient populations, ethical concerns with placebo groups, or urgency in life-threatening conditions. In such contexts, historical controls—data from…

Rare and Orphan Disease Trials, Trial Design & Methodology

Implementing Adaptive Designs in Rare Disease Clinical Trials

August 21, 2025

digi

Implementing Adaptive Designs in Rare Disease Clinical Trials How Adaptive Designs Enhance Rare Disease Clinical Trial Efficiency Why Adaptive Designs Are Ideal for Rare Disease Trials Traditional randomized controlled trials (RCTs) often face feasibility issues in rare disease drug development due to small patient populations, recruitment difficulties, and ethical concerns over placebo use. Adaptive designs—clinical…

Rare and Orphan Disease Trials, Trial Design & Methodology

Implementing Risk-Based Monitoring in Rare Disease Trials

August 20, 2025

digi

Implementing Risk-Based Monitoring in Rare Disease Trials How to Apply Risk-Based Monitoring in Rare Disease Clinical Research Why Risk-Based Monitoring Is Essential in Rare Disease Trials Risk-Based Monitoring (RBM) has become a cornerstone of modern clinical trial management, replacing traditional 100% on-site Source Data Verification (SDV) with a more strategic, data-driven approach. For rare disease…

Operational Challenges, Rare and Orphan Disease Trials

Using AI to Identify Rare Disease Trial Candidates

August 20, 2025

digi

Using AI to Identify Rare Disease Trial Candidates Harnessing Artificial Intelligence to Improve Rare Disease Trial Candidate Identification The Challenge of Identifying Patients in Rare Disease Trials Recruiting patients for rare disease clinical trials is notoriously difficult due to low prevalence, heterogeneous clinical presentations, and long diagnostic odysseys. Traditional recruitment methods often fail because they…

Data & Technology, Rare and Orphan Disease Trials

Case Study: Rare Oncology Successes in Ultra-Small Populations

August 16, 2025

digi

Case Study: Rare Oncology Successes in Ultra-Small Populations Breakthrough Oncology Approvals in Ultra-Small Patient Populations Introduction: The Challenge of Rare Oncology Trials Rare cancers, such as sarcomas, pediatric malignancies, and ultra-rare leukemias, represent one of the most challenging landscapes in drug development. Traditional randomized controlled trials requiring hundreds or thousands of patients are often impossible…

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials

August 14, 2025

digi

Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials How to Secure FDA Orphan Drug Designation in Rare Disease Clinical Trials Understanding the FDA Orphan Drug Designation The Orphan Drug Designation (ODD) program, administered by the U.S. Food and Drug Administration (FDA), was established under the Orphan Drug Act of 1983 to…

Rare and Orphan Disease Trials, Regulatory Frameworks

Case Study: Overcoming Recruitment Barriers in Rare Disease Trials

August 12, 2025

digi

Case Study: Overcoming Recruitment Barriers in Rare Disease Trials Lessons from Overcoming Recruitment Barriers in Rare Disease Clinical Trials Introduction: Why Recruitment Is the Greatest Barrier in Rare Disease Research Recruitment remains the single most critical challenge in rare disease clinical trials. With patient populations often numbering in the hundreds—or even dozens—globally, traditional recruitment approaches…

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

The Role of Natural History in Rare Disease Research

August 11, 2025

digi

The Role of Natural History in Rare Disease Research Understanding Natural History Studies in Rare Disease Research Introduction: Why Natural History is a Cornerstone in Rare Disease Trials Rare diseases, by definition, affect small patient populations and often lack established standards of care. As a result, there is a significant knowledge gap in understanding how…

Natural History Studies, Rare and Orphan Disease Trials

Regulatory Guidance on Adaptive Methods in Rare Disease Trials

August 10, 2025

digi

Regulatory Guidance on Adaptive Methods in Rare Disease Trials Navigating Regulatory Guidance on Adaptive Designs in Rare Disease Trials Introduction: Regulatory Confidence in Adaptive Methods Adaptive designs offer a lifeline for efficient clinical development in rare diseases, where patient populations are small and traditional trial models are often unfeasible. However, this flexibility must operate within…

Adaptive Trial Designs, Rare and Orphan Disease Trials

Seamless Phase II/III Trials in Orphan Indications

August 8, 2025

digi

Seamless Phase II/III Trials in Orphan Indications Accelerating Rare Disease Drug Development with Seamless Phase II/III Trial Designs Introduction: Why Seamless Designs Matter in Rare Diseases Traditional clinical trials follow a linear sequence—Phase I to Phase III—often resulting in delays and duplication of efforts. For orphan indications, where patient populations are scarce and unmet needs…

Adaptive Trial Designs, Rare and Orphan Disease Trials